Additional file 6: of Nilotinib (Tasignaâ ˘) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
收藏数据链接：
官方服务：
资源简介：
List of 106 pathways significantly downregulated in improvers post treatment (false discovery rate (FDR) <5 %). The FDR is provided for each pathway. (XLSX 13 kb)
创建时间：
2016-12-15
